Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of telaprevir dosing schedules with peginterferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C
NL-OMON30970Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telaprevir in hepatitis C virus infection (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Undetectable HCV RNA at all assessment time points and end of treatment, Time to first undetectable HCV RNA and 6 more. Started Oct 2007; status: active, not recruiting.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON30970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30970.